AzTrials
AzTrials

Congenital CataractNCT03240796

Secondary Intraocular Lens Implantation in Pediatric Patients

A study testing minimal invasive surgery and secondary IOL implantation and traditional cataract surgery and secondary IOL implantation in people with Congenital Cataract, run by Sun Yat-sen University at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This prospective, non-randomized controlled study aiming at comparing the prognosis of minimal invasive lens surgery and traditional cataract surgery for treating congenital cataracts after the patient receives secondary intraocular artificial lens (IOL) implantation. Read more about this study

Who is it for?
Ages 24 to 72 months
Conditions the study is for
Congenital Cataract
What is being tested?
minimal invasive surgery and secondary IOL implantation and traditional cataract surgery and secondary IOL implantation
Could I receive a placebo?
No, everyone receives an active treatment
How many people
80 participants
Where
1 siteChina
Study dates
1 Aug 2017to Dec 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 24 to 72 months
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Age between 24 months and 72 months Uncomplicated congenital cataract and underwent cataract removal Informed consent signed by a parent or legal guardian

Who cannot join

  • Intraocular pressure >21 mmHg at enrollment Preterm birth (<28 weeks) Presence of other ocular diseases (keratitis, keratoleukoma, aniridia, glaucoma) or systemic disease (congenital heart disease, ischemic encephalopathy) History of ocular diseases (any congenital eye diseases, such as, congenital cataract, congenital glaucoma, congenital aniridia) in the family History of ocular trauma Microcornea Persistent hyperplastic primary vitreous Rubella Lowe syndrome

Trial locations and contacts

1 site in 1 country.

China1 site, 1 recruiting
  • Zhongshan Ophthalmic Center,Sun Yat-sen U

    Guangzhou, Guangdong, 510060

    Haotian Lin, Phd, +86-20-87330475, gddlht@gmail.com

    Haotian Lin, PhD

    Recruiting

Other trials in China

About this study

Official title: Secondary Intraocular Lens Implantation in Pediatric Patients: Minimal Invasive Surgery vs. Traditional Cataract Surgery for Treating Congenital Cataracts

This prospective, non-randomized controlled study aiming at comparing the prognosis of minimal invasive lens surgery and traditional cataract surgery for treating congenital cataracts after the patient receives secondary intraocular artificial lens (IOL) implantation.

Read the detailed description

Pediatric patients received minimal invasive surgery and traditional lens removal surgery (anterior capsulorhexis and irrigation/aspiration and posterior capsulorhexis and anterior vitrectomy) are enrolled. The patients are assigned to two groups according to the strategy of primary surgery: Group I: the participants received minimal invasive surgery, while in Group II, the participants received a traditional cataract surgery. Investigators perform a secondary intraocular lens implantation for the patients. Investigators compare the visual acuity, incidence of high intraocular pressure, incidence of visual axis opacification, uveitis and iris/pupil abnormality between two groups after the first and the second surgery, aiming at comparing the prognosis of minimal invasive lens surgery and traditional cataract surgery for treating congenital cataracts.

Being tested
minimal invasive surgery and secondary IOL implantation, traditional cataract surgery and secondary IOL implantation
Keywords
congenital cataract, intra-capsular IOL implantation, ciliary sulcus fixation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • minimal invasive surgery and secondary IOL implantationProcedure or surgery

    We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter and moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities. Secondary IOL implantation: implant the IOL either into the capsule bag or fix at the ciliary sulcus.

  • traditional cataract surgery and secondary IOL implantationProcedure or surgery

    traditional cataract surgery: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy (ACCC+ I/A + PCCC + Anti-vit).

    Secondary IOL implantation: implant the IOL either into the capsule bag or fix at the ciliary sulcus.

Study groups in NCT03240796
Study groupRoleWhat they receive
minimal invasive surgery and secondary IOL implantationExperimentalNot described
Receives: Procedure: minimal invasive surgery and secondary IOL implantation
traditional cataract surgery and secondary IOL implantationActive comparatorNot described
Receives: Procedure: traditional cataract surgery and secondary IOL implantation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Best corrected visual acuity

    measured using the Teller's acuity card, the Lea symbol visual acuity chart or the ETDRS chart according to the patient's age.

    Measured: recorded at each follow-up (one week, one month, three months, six months after surgery, and every six months thereafter)

Secondary outcomes (3)
  1. Visual axis opacification

    Visual axis opacification was recorded by standardized slit lamp retroillumination.

    Measured: recorded at each follow-up (one week, one month, three months, six months after surgery, and every six months thereafter)

  2. High intraocular pressure

    measured with Tono-pen tonometer

    Measured: recorded at each follow-up (one week, one month, three months, six months after surgery, and every six months thereafter)

  3. Bi-ocular visual function

    determined with synoptophore

    Measured: The examination is performed when the patient is four years old and older, once a year.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Aug 2017
  2. Study start1 Aug 2017
  3. Primary completionDec 2019 (estimated)
  4. Study completionDec 2019 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
80 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03240796
Sponsor's protocol ID
CCPMOH2017-China-4
Status last verified
Apr 2019
First submitted
26 Jul 2017
Last updated
10 Apr 2019
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing minimal invasive surgery and secondary IOL implantation and traditional cataract surgery and secondary IOL implantation in people with Congenital Cataract, run by Sun Yat-sen University at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 10 Apr 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Jing Li, M.D (+86-20-87330341, Reviewborad_SYsU@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Best corrected visual acuity (time frame: recorded at each follow-up (one week, one month, three months, six months after surgery, and every six months thereafter)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Apr 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in